Most material SEC filings — October 28, 2026

On October 15, 2026, Penske Automotive Group entered into a merger agreement with Motown Acquisition Corp. (owned by Penske Corporation 64% and Mitsui & Co., Ltd. 36%) to be taken private. Public shareholders will receive $212.00 per share in cash, valuing the company at ~$16.3 billion enterprise value. Transaction expected to close Q1 2027. Q3 2026: revenue $8.4B (+5% YoY), net income $221M, EPS $3.36 (including $6.3M transaction costs). Nine-month 2026: revenue $24.8B, net income $716M, EPS $10.89. Company will cease public reporting upon completion.

Power REIT adjourned its October 27, 2026 Annual Meeting to November 10, 2026 to allow more time for shareholders to vote on Proposal 3, an amendment to resolve the Series A Preferred Stock capital structure issue. The vote requires approval by a majority of all Common Shares outstanding (record date September 11, 2026); non-votes count as votes against. ISS recommended approval, warning that failure to resolve the Series A overhang would likely trigger NYSE American delisting and Exchange Act deregistration, which would end public trading, reduce liquidity, and trigger conversion rights of Series A holders.

On October 23, 2026, Beneficient filed a motion to intervene in Delaware Chancery Court seeking to invalidate approximately $130 million of purported HCLP debt and recover ~$211 million previously paid, alleging former CEO Brad Heppner fabricated the obligations as part of a criminal scheme for which he was convicted in May 2026. Success would leave the company with an unleveraged balance sheet; no consensual resolution has been reached yet.

EnerSys and its merger subsidiary entered into a merger agreement dated October 27, 2026 to acquire Ultralife Corporation for $16.00 per share in an all-cash tender offer, with subsequent statutory merger under Delaware law Section 251(h). The transaction values Ultralife at approximately $266.6M (16.66M shares outstanding × $16.00), with Supporting Stockholders (Bradford Whitmore and related entities) committing shares via support agreement. Closing expected within two business days post-tender offer completion; regulatory approvals required under HSR, NSIA, and foreign antitrust laws.

Palvella announced FDA acceptance and Priority Review of its NDA for QTORIN rapamycin for microcystic lymphatic malformations, with a PDUFA target action date of February 28, 2027. The Phase 3 SELVA study achieved statistical significance across all six prespecified efficacy endpoints (p<0.001), with 95% of participants ≥6 years old showing improvement on the primary endpoint. The company is preparing for a potential standalone U.S. commercial launch in H1 2027, contingent on FDA approval.

Trian Fund Management (16.3% owner), Flynn Group LP, BlueFive Capital, and Sixth Street Partners submitted a non-binding proposal on October 28, 2026 to acquire all Wendy's shares not currently held by Trian for $7.35 per share in cash—a ~20% premium to the October 27 closing price. The transaction assumes 194.0 million fully-diluted shares outstanding, valuing the company at ~$1.425 billion (excluding Trian's 16.3% stake). No financing condition; Trian would roll over its shares; advisors include J.P. Morgan, BofA Securities, and Debevoise Plimpton. A cooperation agreement between Trian and Flynn establishes 12-month exclusivity and 50/50 expense sharing.

Evolution Metals Technologies (market cap ~$7.1M) announced delivery of 57 ULVAC sintered magnet production equipment containers to its Pohang, South Korea facility on October 28, 2026, with commissioning beginning November 2026. The equipment supports a tenfold capacity expansion from ~1,000 to ~10,000 metric tons annually. Simultaneously, the company signed an investment framework with Pohang City securing approximately US$28 million in local government grant funding (subject to conditions), representing ~394% of the company's current market capitalization. Additional details: the company has a $100M convertible financing facility with Yorkville Advisors, has secured >50% of input materials outside China, holds Tier-1 OEM certifications across eight grades, and operates 880 MW of committed power infrastructure.

On July 14, 2026, Glucotrack merged with Lokahi Therapeutics, acquiring its assets for $34.3M in consideration (19.99% common stock + Series A preferred representing 90% total equity post-merger), valued at $12.522/share. Concurrently, Glucotrack raised $7.95M gross in bridge financing ($4.45M on 7/14, $3.5M on 8/4, both convertible notes at 8% coupon, 22% OID, maturing 4-5/2027) plus $2M interim PIPE. The company executed two reverse stock splits: 1-for-15 (8/28/2026) and 1-for-2 (10/26/2026), totaling 1-for-30 combined. Pro forma shows combined H1 2026 net loss of $19.7M on $0 revenue; accumulated deficit reaches $165.4M.

On October 26, 2026, Eureka Acquisition Corp (total assets ~$33.6M) received a notice under Item 3.01 regarding delisting or failure to satisfy continued listing rules. The filing indicates a transfer of listing is occurring. No specific dollar amounts, counterparties, or detailed remediation terms are disclosed in the available filing text.

Transcode Therapeutics engaged Tungsten Advisors on October 28, 2026, to lead a formal strategic process evaluating potential transactions for the company and its lead program TTX-MC138 (Phase 2a RNA therapeutic for colorectal cancer). Options include licensing individual assets, development partnerships, portfolio sales, or business combinations. No transaction timeline or specifics disclosed; board will update only if a definitive transaction is approved.

Mistras Group's 40-calendar-day go-shop period under its merger agreement with H.I.G. Capital expired October 27, 2026 with no alternative acquisition proposals received. H.I.G. remains on track to acquire Mistras for $20.35/share in all-cash, representing ~$866M enterprise value including debt. Transaction expected to close late 2026 or early 2027 pending stockholder approval (special meeting November 24, 2026) and regulatory approvals.

On October 23, 2026, Milestone Pharmaceuticals received a notice from its listing exchange regarding failure to satisfy continued listing standards. The company trades under ticker symbol MIST (CIK 0001408443). No specific cure period, financial metrics, or remediation details are disclosed in this 8-K filing.

GridAI Technologies Corp. advanced $5,000,000 total to Pronghorn Resources, LLC via a third amended and restated secured convertible note dated October 22, 2026. The loan consists of three tranches: $2,000,000 (July 17, 2026), $964,000 (September 4, 2026), and $536,000 (October 1, 2026), totaling $3,500,000 previously, plus a fourth advance of $1,500,000 (October 22, 2026). The note matures December 31, 2026 or upon change of control; bears 7% annual interest; converts to 10% of Pronghorn's fully diluted equity upon event of default; is secured by Pronghorn's assets under a security agreement.

10% owner Portman David J. (LONA) bought 3.1M shares (~$9.9B) on the open market (50% of holdings). Open-market insider purchase — historically a bullish signal.

Sterling Infrastructure posted Q3 2026 revenue of $1.564B (+127% YoY), net income of $214.9M (+133%), and adjusted diluted EPS of $7.58 (+118%), driven by the CEC electrical acquisition (Sept 2025, contributing $425.6M in Q3 2026). Full-year 2026 guidance raised to $4.63–4.73B revenue (88% growth), $21.70–21.96 adjusted diluted EPS (101% growth), and $970–981M adjusted EBITDA (94% growth). Signed backlog is $4.14B (+61% YoY); combined backlog including unsigned awards totals $6.14B (+78% YoY). Company deployed $107.3M on buybacks YTD 2026.

Teradyne reported Q3 2026 revenue of $1,306M (up 70% from $769M in Q3 2025), with GAAP diluted EPS of $2.17 (up 189% from $0.75). Non-GAAP diluted EPS was $2.29 vs $0.85 prior year. Semiconductor Test contributed $1,072M, Product Test $138M, Robotics $96M. Gross margin was 59.1%. The company provided Q4 2026 guidance of $1,250–$1,350M revenue with GAAP EPS of $1.88–$2.18 and non-GAAP EPS of $1.95–$2.25.

Generac reported Q3 2026 net sales of $1.294 billion (up 16% YoY), with Commercial Industrial segment growing 28% to $552M and Residential up 9% to $743M. The company signed a long-term supply agreement with Amazon.com for $2.4B in backup power generators (deliveries in 2027–2028), bringing total data center backlog to approximately $4.5B. Net income was $109M ($1.83/share); adjusted EBITDA was $256M (19.8% margin). Full-year 2026 sales guidance maintained at mid-to-high teens growth; adjusted EBITDA margin guidance raised to 20.5–21.0% from 20.0–21.0%.

Monomoy Capital Partners submitted an unsolicited, non-binding proposal to acquire LCI Industries for $101 per share in cash. LCI's Board is evaluating the proposal under its fiduciary duties but continues to recommend the all-stock merger with Patrick Industries announced June 30, 2026. The filing provides no information on LCI's current share price, market capitalization implied by the Monomoy bid, or share count needed to calculate total acquisition value.

AXT's majority-owned subsidiary Beijing Tongmei Xtal Technology Co., Ltd. entered into definitive agreements for private equity financing of RMB 1.91–3.67 billion (approximately $285–$545 million) from institutional investors led by an Asia asset manager. Proceeds fund indium phosphide wafer capacity expansion, raw material company growth, and working capital. AXT expects to maintain ~73.4% ownership and consolidate Tongmei post-closing (expected December 2026); the lead investor will guide Tongmei toward an overseas listing.

Prosperity Bancshares completed three mergers in 2026: American Bank Holding (Jan 1, $1.9B assets), Southwest Bancshares/Texas Partners (Feb 1, $1.9B), and Stellar Bancorp (Jul 1, $10.4B). Total assets grew 41.1% to $54.1B; loans grew 45.5% to $32.1B; deposits grew 48.4% to $41.2B. Q3 net income $141.5M ($1.18 EPS); excluding $69.7M merger expenses, adjusted earnings $200.8M ($1.67 EPS). Board approved 6.67% dividend increase to $0.64/share (23rd consecutive annual increase, 10.4% CAGR). Repurchased 1.5M shares YTD at avg $68.63/share for $102.6M.

HF Sinclair reported Q3 2026 net income of $2,015M ($11.38/diluted share), up 400% YoY, driven by refining segment strength ($2,435M income vs. $476M YoY) from elevated crack spreads and EPA RINs waivers. Company returned $572M to shareholders (dividends $93M + buybacks $479M) and maintained $0.525/share quarterly dividend. Leadership transition: Steve Ledbetter (current President/COO) becomes CEO effective Jan 1, 2027, succeeding Franklin Myers who becomes executive chairperson to oversee planned separation of Lubricants & Specialties segment expected complete in 2027; separation to distribute ≥80.1% of subsidiary stock.

AEP reported Q3 2026 operating EPS of $2.23 vs. $1.80 YoY, expects full-year 2026 operating EPS at/above $6.55 high end. Company announced $100B five-year capital plan (2027-2031) with 13%+ rate base CAGR, targeting $162B rate base by 2031; introduced 9-11% annual operating EPS growth guidance 2027-2031 with 10%+ CAGR. New contracted load of 84 GW by 2031 supported by take-or-pay agreements generating up to $21B in residential customer cost offsets. 2027-2028 guidance: $6.75-$7.05 and $7.40-$7.70 per share, respectively.

Dana posted Q3 2026 sales of $2.04B (+$121M YoY), adjusted EBITDA of $218M (10.7% margin, +220 bps), and adjusted EPS of $0.41. The company repurchased 6.6M shares for $200M in Q3 (YTD $369M) and plans ~$100M more in Q4. The transformational Eaton Mobility transaction remains on track to close around end-Q1 2027 with nearly all regulatory approvals obtained; the deal includes $250M+ identified cost synergies and targets New Dana with $14-15B revenue by 2030.

Replimune's lead product TUDRIQEV (vusolimogene oderparepvec-wtpg) achieved commercial availability in the U.S. on October 6, 2026, for advanced melanoma in combination with nivolumab, with >15 institutions prescribing and >70% of 200 priority accounts engaged. Cash increased from $268.9M (March 31, 2026) to $307.8M (September 30, 2026), driven by $141.0M net proceeds from an August 2026 stock and pre-funded warrant offering plus $15.0M debt draw, offsetting $57.1M Q2 FY2027 net loss. Company projects runway exceeding 12 months.

Jay R. Luly, Ph.D., age 70, will retire as President and CEO effective February 1, 2027, after 23 years leading Enanta. He will serve as Strategic Advisor through 2027. Tara L. Kieffer, Ph.D., who joined Enanta in 2020 and most recently served as Chief Product Strategy Officer (after 16 years at Vertex), has been appointed Chief Operating Officer in a newly created role. The Board is conducting a comprehensive search for Luly's successor, considering internal and external candidates.

Benitec announced positive interim results from its BB-301 first-in-human Phase 1b/2a study in oculopharyngeal muscular dystrophy (OPMD). All 9 patients treated (6 low-dose Cohort 1, 3 high-dose Cohort 2) achieved formal responder status for swallowing function improvements, with high-dose cohort showing greater improvements in throat emptying and swallowing capacity at 3-month follow-up (100% vs 67% low-dose for throat emptying; 67% vs 17% for functional capacity). No serious adverse events reported; pivotal study planned for mid-2027.

C.H. Robinson amended its $2B revolving credit facility on October 22, 2026, to support the proposed $5.8B acquisition of RXO, Inc. The amendment permits up to $4.5B in bridge financing and modifies the Net Leverage Ratio covenant from 3.75x to 4.25x for four quarters post-RXO closing. Required lenders include U.S. Bank, Wells Fargo, JPMorgan Chase, Bank of America, Morgan Stanley, BMO, HSBC, PNC, and BNP Paribas. The transaction is expected to close in H1 2027 at $30.25/RXO share, with estimated $300M annual cost synergies.

On October 27, 2026, Olin Corporation amended its credit facilities to support the pending OlinHuntsman Merger with Huntsman Corporation. The Second Amendment refinances existing term loans and revolving commitments into $750M initial term loans and $1.75B revolving commitments (total $2.5B). Concurrent with the merger closing, new lenders provide replacement and additional facilities. Key covenants include leverage ratios declining from 5.50x to 4.00x through Q1 2029, and interest coverage ratios of 2.50x–3.00x. The amendment permits up to $300M in annual merger synergies add-backs (declining to 25% of EBITDA post-collateral release) and includes typical merger-related conditions and pricing adjustments.

FIRST COMMUNITY BANKSHARES INC (Purchaser; Virginia, ~$509.4M market cap) agreed to merge with MAIN STREET FINANCIAL SERVICES CORP (Company; West Virginia) effective October 27, 2026. Company shareholders will receive 0.6174 shares of Purchaser common stock per Company share held. As of agreement date, 7,863,994 Company common shares outstanding; 459,918 Company stock options outstanding. Closing targeted for no later than April 1, 2027 or 15 days after regulatory conditions satisfied. Company Bank (Ohio-chartered) will merge into Purchaser Bank (Virginia-chartered) following the holding company merger.

SkyAI Inc. (market cap ~$5.6M) entered into a Tender Offer Support and Settlement Agreement with Bastion Trading Limited and affiliates on October 27, 2026. Bastion holds 4,649,745 common shares, 4,234,615 cash pre-funded warrants, and 5,384,615 cash stapled warrants. Under the agreement, SkyAI will expand its tender offer to purchase 100% of pre-funded warrants (up from 95%) at $3.00 per warrant and newly add stapled warrants at $0.17 each, extending the offer to November 12, 2026. Bastion committed to tender all its securities and accept a three-year standstill, agreeing not to acquire company securities, nominate directors, or solicit proxies. If fully tendered, the company will pay approximately $214.3 million using $223 million in cash on hand (from prior SOL sales). Company will reimburse Bastion up to $300,000 in documented expenses.

One Stop Systems, Inc. (market cap ~$75.3M) entered into an Equity Distribution Agreement with Piper Sandler Co. on October 28, 2026, authorizing the issuance and sale of up to $50,000,000 in common stock through an at-the-market (ATM) offering program. The Agent will receive a 3.0% sales commission. Shares cannot be sold below $0.50/share or if subject to trading restrictions. The agreement is effective for three years from Registration Statement effectiveness (September 2, 2026).

Amendment No. 1 to the April 3, 2026 voting agreement among MGM Resorts, People Incorporated (formerly IAC), and Barry Diller became effective October 27, 2026. The Covered Entities (People and Diller entities) beneficially own 66,822,350 MGM shares. Key changes: (1) voting obligations now apply only to shares exceeding a 'Voting Cap Threshold' on ordinary matters, with excess shares voted with majority; (2) on Change of Control votes, all shares must vote per Board recommendation if conditions are met; (3) new standstill cap at 29.9% of outstanding shares; (4) added restrictions on company defensive measures against Covered Entities; (5) specific performance and amendment-by-written-consent-only provisions added.

Nasdaq's Hearings Panel granted Rain Enhancement Technologies (RAIN; market cap ~$7.3M) a conditional extension to maintain Nasdaq Capital Market listing. The company must satisfy milestones related to its proposed business combination with Tensor Networks and related financing by February 16, 2027, with the combined entity achieving full Nasdaq listing compliance by that date. No specific dollar amounts, financing targets, or deal terms are disclosed in this filing.

Effective June 1, 2026, FedEx completed the spin-off of FedEx Freight into a separate publicly traded company (retaining 19.9% equity interest), changed its fiscal year-end from May 31 to December 31, and reorganized segment reporting into Express U.S. Domestic and Express International. On October 1, 2026, FedEx sold its Supply Chain business to CMA CGM Group for $1.4 billion. Q2 2026 (calendar) net income was $6.129B (including $4.492B gain on retained FedEx Freight investment), with diluted EPS of $25.28.

On June 3, 2026, Cycurion (market cap ~$10.1M) acquired 100% of Secuvant LLC for $2.875M in upfront consideration ($875K cash + 888,888 shares of Series I preferred stock valued at $2M), plus contingent earn-out of up to $3.12M over three years if revenue/margin targets met. Secuvant: $2.3M revenue (2025), $0.8M net income (2025); but declining billings (down 15% in 2025, 31% in H1 2026), concentrated customer base (60% from one customer), working capital deficit, and both companies flagged substantial going-concern doubt. Consideration represents ~59% of Cycurion's public market value; material relative to acquirer size.

Cohu reported Q3 2026 net sales of $173.0M (up 37% YoY from $126.2M), with GAAP net income of $12.1M ($0.22/share) and non-GAAP net income of $23.3M ($0.43/share). Bookings increased 126% YoY with systems bookings up 318% and recurring up 36%. The company raised full-year 2026 high-performance computing revenue guidance to ~$120M and projects Q4 2026 sales of $178M ± $7M (46% YoY growth). Cash and investments totaled $507.9M; no share repurchases occurred.

Viking Therapeutics closed concurrent offerings of common stock and convertible senior notes for ~$575M gross proceeds in September 2026, bringing cash to $960M at quarter-end. The company advanced VK2735 (dual GLP-1/GIP agonist) into Phase 3: VANQUISH trials (subcutaneous, 5,500 patients enrolled) continue on track for 2027 completion, and SUNRISE trials (oral formulation, targeting 1,120 patients) initiated in October 2026. Positive maintenance dosing data showed VK2735 retained 82-97% weight loss at lower frequencies (monthly/every-other-week dosing); Part 2 maintenance study launched. Early-stage VK3019 (amylin agonist) Phase 1 SAD study nearing completion. Q3 2026 R&D expenses surged to $166.8M (vs. $90.0M YoY); net loss $183.2M ($1.55/share); 9M 2026 net loss $469.5M. Balance sheet: $960M cash vs. $706M year-end 2025.

Glaukos reported Q3 2026 net sales of $211.0 million, up 58% YoY, driven by iDose TR (≈$76M in Q3) and Epioxa (≈$53M in Q3). Non-GAAP gross margin 88% (up 4pp YoY); non-GAAP diluted EPS $0.47 vs. ($0.16) loss in Q3 2025. Company raised full-year 2026 guidance to $775–785M (from $680–700M) and introduced preliminary 2027 guidance of $1 billion. Cash increased $50.5M to $339.8M; no debt.

On October 2, 2026 effective January 4, 2027, NeoGenomics amended employment agreements for two executives and terminated a third. Anthony Zook transitions from CEO to Executive Chairman with $400,000 base salary and $3,000,000 target annual equity (down from prior CEO terms). Warren Stone becomes new CEO with $850,000 base salary, $850,000 target bonus (100% of base), and $8,000,000 target annual equity. Alicia Olivo (EVP General Counsel) separated October 2, 2026 receiving 12 months base salary continuation ($564,000), one-time bonus of $338,400, 12 months COBRA, and accelerated vesting of 12-month time-based equity grants.

Arxis reported Q3 2026 revenue of $564M (36% YoY), with net income of $84M vs. $(10)M loss in Q3 2025. Adjusted EBITDA reached $256M (67% growth). The company raised FY2026 guidance to $2,050–$2,070M revenue (from $1,960–$1,980M) and $855–$865M Adjusted EBITDA (from $790–$800M). It introduced 2027 guidance: $2,400–$2,500M revenue (17–21% growth) and $1,010–$1,060M Adjusted EBITDA. YTD 2026 acquisitions include Omnetics (completed Aug 17, 2026), Schatz Bearing, and StratEdge (combined $151M purchase price in Sept 2026), plus three others. Net leverage improved to 1.6x at Sept 30, 2026 from 4.2x at Dec 31, 2025.

GridAI Technologies Corp. (market cap ~$14.9M) executed a private investment in public equity (PIPE) agreement dated October 22, 2026, for approximately $2.15M aggregate subscription amount across multiple purchasers. The deal includes common shares, pre-funded warrants (exercise price $0.0001), and common warrants (60-month term). Specific dollar amounts per purchaser, share counts, and warrant coverage ratios are left blank in the filing template and were to be finalized in an executed allocation schedule not provided. No counterparty names disclosed. The filing contains boilerplate warrant and purchase agreement terms with standard anti-dilution, cashless exercise, and registration rights provisions.

Luxfer reported Q3 2026 GAAP net sales of $91.7M (down 4.1% YoY), with adjusted net sales declining 3.9% to $89.3M. Adjusted EBITDA fell 10.3% to $12.2M, driven by a 6.6% sales decline in Elektron (defense focus), partially offset by 29.7% EBITDA growth in Gas Cylinders. The company is pending acquisition by Wynnchurch Capital affiliates at $17.37/share in an all-cash transaction; shareholder vote scheduled November 4, 2026, closing expected late November. Net debt stands at $37.8M (0.8x LTM adjusted EBITDA).

Adial Pharmaceuticals changed its corporate name to Azora Therapeutics, Inc., effective October 29, 2026, following its June 2026 acquisition of Azora Therapeutics. Stockholders approved conversion of Series A preferred stock (issued in the acquisition) into common stock. The company raised approximately $32 million in gross proceeds from a private placement led by Coastlands Capital, with potential for an additional $32 million upon Phase 1 initiation of lead asset AT177 (an oral AhR agonist for ulcerative colitis), planned for H1 2027. New executive leadership includes Matt Davidson (CEO, former Verrica founder) and Julie Saiki (Chief Strategy Officer, UC patient and scientist).

Preformed Line Products reported Q3 2026 net sales of $209.5M (+18% YoY) with gross margin of 33.4% (+370bps). Diluted EPS was $3.56 (+$3.03 YoY, or +70% adjusted for prior-year pension termination charges). Nine-month 2026 sales reached $598.5M (+21% YoY) with diluted EPS of $10.18 (+88% YoY, or +46% adjusted). The company completed the May 2026 acquisition of Delta Star Conetores Electricos Ltda and ended Q3 with $99.3M cash, $53.9M available credit, and operating cash flow up 95% YoY.

Darling reported Q3 2026 net income of $267.0M ($1.67 diluted EPS) vs. $19.4M ($0.12 EPS) in Q3 2025, with total net sales of $1.8B (up 14.5% YoY). Combined Adjusted EBITDA was $514.3M vs. $244.9M YoY, driven by Diamond Green Diesel (50% ownership) generating $204.2M EBITDA ($1.30/gallon on 314.9M gallons sold). Company reduced net debt by $420M to $3.37B, repurchased $75.9M common stock, and received $171M in cash distributions from DGD (including $137.6M from production tax credit sales). Leverage ratio improved to 1.7X from 2.9X at year-end 2026. FY2026 Combined EBITDA guidance reaffirmed at $2.2-2.3B.

Geron discontinued the Phase 3 IMpactMF trial evaluating imetelstat in JAK inhibitor relapsed/refractory myelofibrosis based on an independent Data Monitoring Committee recommendation that the trial was unlikely to meet its primary overall survival endpoint. The trial enrolled 327 patients in a 2:1 randomized design comparing imetelstat (9.4 mg/kg IV every 3 weeks) to best available therapy. No new safety signals were identified. The company plans detailed data analysis and future scientific publication while focusing on growing RYTELO (imetelstat) demand in its approved lower-risk myelodysplastic syndrome indication.

Webster Financial Corporation filed an amended 8-K disclosing Q2 2026 results within a transformational acquisition context. Webster agreed February 3, 2026 to be acquired by Banco Santander for ~$12.3 billion ($48.75 cash + 2.0548 ADSs per common share); stockholder approval received May 26, 2026, OCC approval June 12, 2026, ECB approval July 21, 2026. Pending Federal Reserve approval, expected to close H2 2026. Q2 net income $256.8M (Q1: $256.8M); six-month net income $503.0M vs. $485.8M prior year. Acquisition costs: $8.7M (Q2), $17.9M (six months). Despite pending transaction, Webster maintains normal operations with $85.9B total assets (up from $84.1B year-end 2025), $70.3B deposits (up from $68.8B), 11.71% CET1 ratio (well-capitalized).

Actuate Therapeutics completed an underwriting agreement with Newbridge Securities on Oct 26, 2026 to sell 30,985,900 common shares at $0.355/share plus 15,492,950 common warrant shares (exercise price $0.45), plus up to 4,647,885 option shares and 2,323,942 option warrant shares (15% over-allotment). Combined gross proceeds ~$20.4M before expenses; net to company ~$19.2M after 7% underwriting discount. Warrants exercisable 180 days post-effective through 5-year term; underwriter receives 3.5% warrant coverage.

Star Equity Holdings (public, ~$12.2M market cap) is acquiring Phil's Welding, Inc. and related entities (Target Company, Real Estate Company, Parent Company) from sellers Leah Davis and Phillip Davis via two mergers. Total consideration: $350K cash + 75K shares Series A Preferred (Operating Co.) + $150K cash + 35K shares Series A Preferred (Real Estate), totaling approximately $850K in base consideration, subject to working capital and debt adjustments. Initial Closing occurred October 23, 2026; Real Estate Closing contingent on EWA (environmental) confirmation by Feb 28, 2027.

TechPrecision Corporation (guarantor) and affiliated borrowers executed the 16th amendment to their loan agreement with Beacon Bank Trust on October 22, 2026. The amendment extends the maturity of a $4.5M revolving line of credit from an unspecified prior date to November 30, 2026, and modifies interest rate terms. However, the filing explicitly acknowledges multiple "Existing Defaults" on debt covenants (Debt Service Coverage Ratio and Balance Sheet Leverage ratios) spanning eight quarters from Sept 2023–June 2025, which remain uncured. The lender reserved all rights to accelerate the debt and demand immediate repayment.